INTRODUCTION
============

Glucose nonfermentative gram-negative bacilli (GNFB) such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii* are opportunistic pathogens that cause infections mainly in hospitalized patients, especially in patients in intensive care units \[[@B1][@B2]\]. Most GNFB are naturally resistant to many antimicrobial agents and also acquire antimicrobial resistance easily. Therefore, GNFB infections are difficult to treat.

Carbapenem is the only available drug for treating GNFB infections in many cases. However, the recent increase of carbapenem resistance in GNFB has become a serious problem worldwide, particularly in Korea \[[@B3]\]. Most carbapenem-resistant *P. aeruginosa* and *A. baumannii* strains identified in Korea are also extensively drug-resistant (XDR) \[[@B4]\]. Few treatment options are currently available for treating infections caused by these notorious pathogens. Colistin (CL) and polymyxin B can be used for treating infections caused by XDR *P. aeruginosa* and *A. baumannii*; however, these drugs are associated with severe side effects, including nephrotoxicity and neurotoxicity \[[@B5]\]. Moreover, identification of appropriate therapeutic concentrations of these drugs in the blood is difficult \[[@B6][@B7]\]. Tigecycline is another promising antibiotic \[[@B8]\]. However, it cannot be used for treating *P. aeruginosa* infections due to natural resistance \[[@B9]\]. Furthermore, some researchers have reported the emergence of tigecycline-resistant *A. baumannii* in some countries \[[@B10][@B11]\]. One classical treatment method often used for treating infections caused by multi-drug resistant (MDR) pathogens is administration of combinations of several antibiotics \[[@B12][@B13][@B14][@B15]\]. Some evidence suggests that these combinations are effective for treating infections caused by XDR GNFB.

In this study, we determined the extent of synergistic effects exerted by antimicrobial combinations on XDR *P. aeruginosa* and *A. baumannii* isolates collected from hospitals in Korea.

METHODS
=======

In all, 77 XDR GNFB isolates (43 *P. aeruginosa* and 34 *A. baumannii* isolates), which were resistant to all tested antibiotics, except CL, were collected from eight university hospitals in Korea in 2007. Antimicrobial susceptibilities of these isolates were initially tested at each hospital by using CLSI disk diffusion method or Vitek 2 system (bioMerieux, Marcy l\'Etoile, France).

The species of each isolate was determined at a coordinating laboratory, and minimum inhibitory concentration (MIC) of each antibiotic (piperacillin, piperacillin-tazobactam, ampicillin-sulbactam \[AMS\], cefotaxime, ceftazidime \[CAZ\], cefepime, aztreonam, imipenem \[IPM\], meropenem, gentamicin, amikacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and CL) was determined by using CLSI agar dilution method \[[@B16]\].

The ability of each isolate to produce carbapenemases and metallo-β-lactamases (MBLs) was screened by Hodge test \[[@B17]\] and IPM-EDTA sodium mercaptoacetic acid double-disk synergy test \[[@B18]\], respectively. Results of these tests were confirmed by PCR to determine the presence of *bla*~VIM~, *bla*~IMP~, *bla*~SIM~, and *bla*~OXA~ (*bla*~OXA-23~, *bla*~OXA-24~, *bla*~OXA-51~, and *bla*~OXA-58~) \[[@B19]\]. DNA was extracted from whole-cell lysates by boiling bacterial colonies. Amplification was performed in a 20-µL reaction mixture containing 1-µL heat-extracted DNA template, 10 pmol of each primer, and PreMix (Bioneer, Cheongwon, Korea) containing 1 U Taq DNA polymerase. Sizes of amplified products were confirmed by performing electrophoresis, and each confirmed amplified product was sequenced twice by using an automatic sequencer (model 3730xl; Applied Biosystems, Weiterstadt, Germany).

Checkerboard method was used to determine the degree of *in vitro* synergistic effects exerted by antimicrobial combinations used on 30 randomly selected isolates of XDR *P. aeruginosa* and *A. baumannii* each \[[@B20]\]. Antimicrobial combinations tested were IPM and CL, rifampin (RIF) and CL, and CAZ and CL for *P. aeruginosa* and IPM and CL, IPM and AMS, IPM and RIF, and RIF and CL for *A. baumannii*. Fractional inhibitory concentration index (FICI) was calculated by using the following formulae:

FICI were interpreted as follows: ≤0.5, synergistic effect; 0.5-4, additive/indifferent effect; and ≥4, antagonistic effect. *Escherichia coli* (ATCC 25922) and *P. aeruginosa* (ATCC 27853) strains were used for quality control.

RESULTS
=======

None of the XDR GNFB isolates examined was susceptible to any of the tested antibiotic, except CL. The MICs of β-lactams, aminoglycosides, and fluoroquinolones were very high for majority of XDR *P. aeruginosa* and *A. baumannii* isolates ([Table 1](#T1){ref-type="table"}). However, 38% (3/8) of MBL-producing *P. aeruginosa* isolates were intermediately sensitive to aztreonam and 86% (6/7) of OXA-23-negative *A. baumannii* isolates were intermediately sensitive to IPM.

Of the 43 XDR *P. aeruginosa* isolates, four were IMP-1- and VIM-2-producing isolates. Of the 34 XDR *A. baumannii* isolates, two were IMP-1-, VIM-2-, and SIM-1-producing isolates. Most MBL-negative XDR *A. baumannii* isolates yielded positive results for *bla*~OXA-23~ (82%), and all the *A. baumannii* isolates yielded positive results for *bla*~OXA-51~.

In the synergy test, FICI values for the antimicrobial combinations used could not be calculated for three *P. aeruginosa* isolates and five *A. baumannii* isolates because their MICs exceeded the expected values. Three antimicrobial combinations exerted only additive/indifferent effects on all XDR *P. aeruginosa* isolates irrespective of their MBL production status ([Table 2](#T2){ref-type="table"}). Proportions of XDR *A. baumannii* isolates that showed synergistic and additive/indifferent inhibition after treatment with the antimicrobial combinations used are as follows: IPM-AMS, 17% and 80% isolates, respectively; IPM-RIF, 13% and 81% isolates, respectively; IPM-CL, 13% and 87% isolates, respectively; and RIF-CL, 20% and 73% isolates, respectively ([Table 3](#T3){ref-type="table"}). Most *A. baumannii* isolates that showed synergistic inhibition produced MBLs. The extent of decrease of MICs in *A. baumannii* isolates ranged from one quarter to one sixteenths (FICI, 0.25-5). MICs of most antimicrobial concentrations tested decreased from high-level resistance range to susceptible and intermediate range ([Table 4](#T4){ref-type="table"}). None of the tested combinations exerted antagonistic effects.

DISCUSSION
==========

The recent increase in XDR GNFB infections in health-care settings has threatened public health in many countries. In Korea, the recent rates of carbapenem resistance are moderate to high for *P. aeruginosa* and *A. baumannii*. Moreover, MDR and XDR *P. aeruginosa* and *A. baumannii* isolates are commonly identified in Korea. Carbapenem resistance can result from enzyme production, porin loss, and active efflux. However, it is difficult to determine the exact mechanisms underlying carbapenem resistance, except enzyme production. Mechanisms underlying carbapenem resistance could not be determined for most *P. aeruginosa* isolates, except eight (19%) MBL-producing isolates ([Table 2](#T2){ref-type="table"}). Porin loss and active efflux might be the reasons for carbapenem resistance in most *P. aeruginosa* isolates examined in this study. Majority of XDR *A. baumannii* isolates produced β-lactamases, including MBLs and OXA-23 ([Table 3](#T3){ref-type="table"}).

Polymyxin B and polymyxin E (CL) are regarded as the last resort for treating infections caused by MDR or XDR gram-negative pathogens because of the recent spread of antibiotic resistance in many gram-negative bacilli even though severe toxicity. Two studies have suggested that polymyxin B and CL are good treatment options because many XDR *P. aeruginosa* and *A. baumannii* isolates were susceptible to these drugs \[[@B21][@B22]\], which was consistent with the present results ([Table 1](#T1){ref-type="table"}). Resistance to polymyxins has been rarely observed recently; however, several mechanisms through which bacteria may acquire resistance to polymyxin B and CL have been proposed \[[@B23][@B24]\]. A study by Matthaiou et al. \[[@B25]\] showed a relationship between inappropriate use of CL and development of resistance in *P. aeruginosa* and *A. baumannii*. Furthermore, Kim et al. \[[@B26]\] recently reported that mutations in *pmrB* could induce *in vivo* emergence of CL resistance in *A. baumannii* clinical isolates of sequence type 357. Thus, the threat of increasing resistance to polymyxin B and CL is a problem because these drugs need to undergo susceptibility testing before their use in clinical settings. Moreover, limitation of susceptibility method to these drugs may be problematic in clinical microbiology laboratories \[[@B27][@B28]\]. Treatment with polymyxin B and CL has resulted in frequent nephrotoxicity and neurotoxicity, especially in patients with deteriorated renal function. Therefore, close monitoring and caution are often requested during their use. Combination therapy with antibiotics is often used for treating infections caused by MDR or XDR pathogens \[[@B12][@B13][@B14][@B15]\]. Because antimicrobial combinations exerting synergistic effects enable the use of reduced concentrations of individual drugs, such combinations may decrease the possible toxicities associated with high drug concentrations. Polymyxins act primarily on the cell wall by inducing rapid changes in the permeability of the cytoplasmic membrane of gram-negative bacilli, thereby permitting the entry of other antimicrobial agents into the cell. Various antimicrobial agents can be used in combination with CL. Antibiotics that are most frequently combined with CL include β-lactam antibiotics such as carbapenem and RIF. Landman et al. \[[@B29]\] reported that the combination of polymyxin B with IPM or RIF exerted synergistic effects in 80% and 90% cases, respectively, in a time-kill study on *P. aeruginosa*. In a study by Gunderson et al. \[[@B30]\], the combination of CL with CAZ exerted synergistic effects on two CL-susceptible MDR *P. aeruginosa* isolates. However, inconsistent results have been obtained by using the combination of carbapenems with CL for treating infections caused by MDR *P. aeruginosa*. Two studies have found that the combination of CL with meropenem only exerted additive/indifferent effects on MDR *P. aeruginosa* \[[@B31][@B32]\]. A recent meta-analysis by Zusman et al. \[[@B15]\] involving 39 publications and 15 conference proceedings related to the *in vitro* examination of the combinations of polymyxins with carbapenems showed that the combination of polymyxins with IPM exerted synergistic effects on 60% *P. aeruginosa* isolates tested and antagonistic effects on 21% *P. aeruginosa* isolates tested.

Use of combination therapy can suppress the development of resistance *in vitro*. In this study, both IPM-CL and CAZ-CL only exerted additive/indifferent effects and did not exert synergistic effects on all XDR *P. aeruginosa* isolates irrespective of their MBL production status ([Table 3](#T3){ref-type="table"}). The combination of CL with RIF is generally recommended in regimens for treating infections caused by MDR and XDR gram-negative pathogens. However, the rates of synergy exerted by RIF-CL against different *P. aeruginosa* isolates ranged from 5.7% (2/35) to 16.6% (1/6) \[[@B31][@B33]\]. Moreover, RIF-CL did not exert synergistic effects on any *P. aeruginosa* isolate in the present study ([Table 2](#T2){ref-type="table"}). The reason for this discrepancy is unknown, and further evaluation may be required to completely determine the effect of RIF-CL on various *P. aeruginosa* isolates.

The combination of sulbactam, which is effective against *A. baumannii* \[[@B34]\], with IPM exerted a synergistic effect on approximately 17% (5/30) XDR *A. baumannii*, of which four isolates produced MBLs. RIF exhibits bactericidal activity against *A. baumannii* *in vitro*. A study by Timurkaynak et al. \[[@B31]\] showed that 64% of 25 MDR *A. baumannii* isolates were susceptible to RIF. Combinations of RIF with β-lactam antibiotics were effective in mouse model of *A. baumannii*-induced pneumonia \[[@B35][@B36]\]. However, IPM-RIF only exerted a synergistic effect on as low as 13% (4/30) XDR *A. baumannii* isolates in our study. Many studies have shown that CL monotherapy is effective against MDR and XDR *A. baumannii* and that CL-RIF exerts synergistic and bactericidal effects \[[@B37][@B38]\]. In this study, the rates of synergy exerted by IPM-RIF and RIF-CL were 13% and 20%, respectively ([Table 3](#T3){ref-type="table"}).

A study conducted in the UK by Wareham et al. \[[@B39]\] reported that combinations of polymyxin B with IPM, RIF, or azithromycin did not exert any synergistic effect on OXA-23-producing MDR *A. baumannii* isolates. We also observed that the rates of synergy of antimicrobial combinations were higher in MBL-producing *A. baumannii* isolates than in MBL-negative *A. baumannii* isolates ([Table 3](#T3){ref-type="table"}). However, a recent meta-analysis showed that combinations of polymyxins with IPM exerted synergistic effects on 56% *A. baumannii* isolates tested \[[@B15]\]. Among the antimicrobial combinations that exerted synergistic effects, MICs of IPM, AMS, and RIF decreased from resistant or intermediate range to susceptible range ([Table 4](#T4){ref-type="table"}). Moreover, the MIC of CL when used in combination decreased by 2-8 times compared with that when used alone. This finding implies that infections caused by isolates that are susceptible to the synergistic effects of antimicrobial combination can be treated by using conventional treatment regimens even when these isolates are resistant to individual drugs. This also means that the possibility of CL toxicity can be reduced. A recent retrospective cohort study involving 236 patients with XDR *A. baumannii*-induced pneumonia found that survival rates (in terms of 28-day mortality) of patients treated with combinations of CL with sulbactam, tigecycline, or carbapenem were superior to those of patients in the control group who were not treated with any active agent against XDR *A. baumannii* \[[@B40]\].

In conclusion, significant proportion of XDR *P. aeruginosa* isolates produced MBLs and majority of *A. baumannii* isolates produced MBL or OXA-23. All the three antimicrobial combinations, i.e., IPM-CL, RIF-CL, and CAZ-CL, exerted additive/indifferent effects on majority of or all XDR *P. aeruginosa* isolates. And, all the four antimicrobial combinations, i.e., IPM-CL, IPM-AMS, IPM-RIF, and RIF-CL, exerted synergistic or additive/indifferent effects on majority of *A. baumannii* isolates. However, clinical studies should be performed to validate the application of these *in vitro* results in patients because *in vitro* synergy may not be the same as *in vivo* synergy and to determine the exact mechanisms underlying *in vivo* synergy.
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###### Antimicrobial susceptibilities of extensively drug-resistant *P. aeruginosa* and *A. baumannii* isolates

![](alm-36-138-i001)

  Antibiotic                      *Pseudomonas aeruginosa* (N=43)            *Acinetobacter baumannii* (N=34)                                                                 
  ------------------------------- --------------------------------- -------- ---------------------------------- ----- ---- ----- --------------- -------- -------- ----- ---- -----
  Piperacillin                    128 to \> 256                     \> 256   \> 256                             0     0    100   \> 256          \> 256   \> 256   0     0    100
  Piperacillin-Tazobactam         128 to \> 256                     \> 256   \> 256                             0     0    100   \> 128          \> 128   \> 128   0     0    100
  Ampicillin-Sulbactam            NT                                                                                             32 to \> 128    64       \> 128   0     0    100
  Cefotaxime                      NT                                                                                             \> 128          \> 128   \> 128   0     0    100
  Ceftazidime                     16 to \> 128                      64       \> 128                             0     0    100   128 to \> 128   128      \> 128   0     0    100
  Cefepime                        32 to \> 128                      128      \> 128                             0     0    100   32 to \> 128    \> 128   \> 128   0     0    100
  Aztreonam                       16 to \> 128                      128      \> 128                             0     19   81    NT                                           
  Imipenem                        8 to \> 128                       32       32                                 0     12   88    8-32            32       32       0     6    94
  Meropenem                       8 to \> 128                       \> 128   \> 128                             0     2    98    32-64           32       64       0     0    100
  Gentamicin                      64 to \> 128                      \> 128   \> 128                             0     0    100   \> 128          \> 128   \> 128   0     0    100
  Amikacin                        32 to \> 128                      \> 128   \> 128                             0     0    100   \> 128          \> 128   \> 128   0     0    100
  Ciprofloxacin                   8 to \> 128                       32       64                                 0     0    100   32-128          64       128      0     0    100
  Trimethoprim-Sulfamethoxazole   NT                                                                                             16 to \> 128    128      \> 128   0     0    100
  Colistin                        0.5-1                             0.5      1                                  100   \-   0     0.5-1           0.5      1        100   \-   0

Abbreviations: MIC, minimum inhibitory concentration; NT, not tested; R, resistant; I, intermediate; S, susceptible.

###### Effects of antimicrobial combinations on extensively drug-resistant *P. aeruginosa* isolates

![](alm-36-138-i002)

  MBL type       N of tested   N of isolates (%) with synergistic effect on                                                                    
  -------------- ------------- ---------------------------------------------- ---------- ------- ------- ---------- ------- ------- ---------- -------
  MBL negative   22            0 (0)                                          22 (100)   0 (0)   0 (0)   22 (100)   0 (0)   0 (0)   22 (100)   0 (0)
  MBL positive   8             0 (0)                                          7 (88)     0 (0)   0 (0)   8 (100)    0 (0)   0 (0)   8 (100)    0 (0)
  IMP positive   4             0 (0)                                          4 (100)    0 (0)   0 (0)   4 (100)    0 (0)   0 (0)   4 (100)    0 (0)
  VIM positive   4             0 (0)                                          3 (75)     0 (0)   0 (0)   4 (100)    0 (0)   0 (0)   4 (100)    0 (0)
  Total          30            0 (0)                                          29 (96)    0 (0)   0 (0)   28 (93)    0 (0)   0 (0)   30 (100)   0 (0)

^\*^FICI value of one strain in the VIM-positive group could not be calculated; ^†^FICI values of two strains in the MBL-negative group could not be calculated.

Abbreviations: FICI, fractional inhibitory concentration index; Syn, synergistic (FICI, ≤0.5); Ad/In, additive/indifferent (FICI, 0.5-4); Ant, antagonistic (FICI, ≥4); MBL, metallo-β-lactamase.

###### Effects of antimicrobial combinations on extensively drug-resistant *A. baumannii* isolates

![](alm-36-138-i003)

  Carbapenemase type   N of tested   N of isolates (%) with synergistic effect on                                                                                                
  -------------------- ------------- ---------------------------------------------- --------- ------- --------- --------- ------- -------- --------- ------- --------- --------- -------
  MBL negative         24            1 (4)                                          22 (92)   0 (0)   1 (4)     23 (96)   0 (0)   2 (8)    22 (92)   0 (0)   3 (13)    21 (87)   0 (0)
  OXA-23 positive      16            1 (6)                                          15 (94)   0 (0)   1 (6)     15 (94)   0 (0)   2 (13)   14 (87)   0 (0)   3 (18)    13 (82)   0 (0)
  OXA-23 negative      8             0 (0)                                          7 (88)    0 (0)   0 (0)     4 (50)    0 (0)   0 (0)    8 (100)   0 (0)   0 (0)     8 (100)   0 (0)
  MBL positive         6             4 (67)                                         2 (33)    0 (0)   3 (50)    1 (17)    0 (0)   2 (33)   4 (67)    0 (0)   3 (50)    1 (17)    0 (0)
  IMP positive         2             1 (50)                                         1 (50)    0 (0)   1 (50)    1 (50)    0 (0)   1 (50)   1 (50)    0 (0)   2 (100)   0 (0)     0 (0)
  VIM positive         2             2 (100)                                        0 (0)     0 (0)   2 (100)   0 (0)     0 (0)   1 (50)   1 (50)    0 (0)   1 (50)    1 (0)     0 (0)
  SIM positive         2             1 (50)                                         1 (50)    0 (0)   0 (0)     0 (0)     0 (0)   0 (0)    2 (100)   0 (0)   0 (0)     0 (0)     0 (0)
  Total                30            5 (17)                                         24 (80)   0 (0)   4 (13)    24 (81)   0 (0)   4 (13)   26 (87)   0 (0)   6 (20)    22 (73)   0 (0)

^\*^FICI value of one isolate in OXA-23-positive group could not be calculated; ^†^FICI values of two isolates in SIM-positive group could not be calculated.

Abbreviations: FICI, fractional inhibitory concentration index; Syn, synergistic (FICI, ≤0.5); Ad/In, additive/indifferent (FICI, 0.5-4); Ant, antagonistic (FICI, ≥4); MBL, metallo-β-lactamase.

###### Concentrations of antibiotic combinations that exerted synergistic effects on extensively drug-resistant *A. baumannii* isolates

![](alm-36-138-i004)

  Combination (N of isolates tested)   Strain No.   MICs of individual antimicrobials (µg/mL)   MICs in combination (µg/mL)   Effect of combination                          
  ------------------------------------ ------------ ------------------------------------------- ----------------------------- ----------------------- ---------------------- ------
  Imipenem-Colistin (4)                             Imipenem                                    Colistin                      Imipenem                Colistin               FICI
  9                                    32           2                                           4                             1                       0.375                  
  11                                   16           2                                           4                             1                       0.5                    
  25                                   32           0.5                                         8                             0.12                    0.5                    
  26                                   64           4                                           8                             0.5                     0.25                   
  Imipenem-Ampicillin-Sulbactam (6)                 Imipenem                                    Ampicillin-Sulbactam          Imipenem                Ampicillin-Sulbactam   FICI
  19                                   32           64                                          8                             16                      0.5                    
  25                                   32           \> 128                                      8                             32                      0.5                    
  27                                   32           8                                           8                             1                       0.375                  
  28                                   8            4                                           2                             1                       0.5                    
  29                                   16           4                                           4                             1                       0.5                    
  30                                   64           8                                           16                            2                       0.5                    
  Imipenem-Rifampin (4)                             Imipenem                                    Rifampin                      Imipenem                Rifampin               FICI
  12                                   64           32                                          16                            8                       0.5                    
  25                                   32           4                                           8                             0.5                     0.375                  
  28                                   16           8                                           4                             2                       0.5                    
  29                                   16           4                                           1                             1                       0.3125                 
  Rifampin-Colistin (6)                             Rifampin                                    Colistin                      Rifampin                Colistin               FICI
  2                                    4            0.5                                         1                             0.12                    0.5                    
  9                                    32           2                                           1                             0.5                     0.156                  
  11                                   32           1                                           8                             0.25                    0.5                    
  25                                   4            0.5                                         1                             0.12                    0.5                    
  26                                   64           2                                           8                             0.5                     0.375                  
  29                                   4            0.5                                         0.5                           0.12                    0.375                  

Abbreviations: MIC, minimum inhibitory concentration; FICI, fractional inhibitory concentration index.
